Monocytes immunoselected via the novel monocyte specific molecule, CD300e, differentiate into active migratory dendritic cells

Journal of Immunotherapy

Volumn 30, Issue 3, 2007, Pages 303-311

  Clark, Georgina J ^a   Jamriska, Lubomira ^a   Rao, Min ^a   Hart, Derek N J ^a  

^a MATER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

CD300e; Monocyte derived dendritic cells

Indexed keywords

ANTIGEN; B7 ANTIGEN; BIOLOGICAL MARKER; CD14 ANTIGEN; CD300E ANTIGEN; CD40 ANTIGEN; CD83 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD300E; SECONDARY LYMPHOID TISSUE CHEMOKINE; TETANUS TOXOID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ARTICLE; CELL ACTIVITY; CELL DIFFERENTIATION; CELL MATURATION; CELL MIGRATION; CELL SELECTION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; HUMAN CELL; MONOCYTE; NORMAL HUMAN; PHENOTYPE; PINOCYTOSIS; PRIORITY JOURNAL; RECEPTOR BINDING; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD14; ANTIGENS, SURFACE; BIOLOGICAL MARKERS; CELL DIFFERENTIATION; CELL MOVEMENT; CHEMOKINES, CC; CYTOKINES; DENDRITIC CELLS; HUMANS; MEMBRANE GLYCOPROTEINS; MONOCYTES; PHAGOCYTOSIS; PHENOTYPE; PINOCYTOSIS;

EID: 34247112723     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cji.0000211342.65964.9e     Document Type: Article

References (14)

1. Clark GJ, Cooper B, Fitzpatrick S, et al. The gene encoding the immunoregulatory signaling molecule CMRF-35A localized to human chromosome 17 in close proximity to other members of the CMRF-35 family. Tissue Antigens. 2001;57:415-423.
2. Clark GJ, Green BJ, Hart DN. The CMRF-35H gene structure predicts for an independently expressed member of an ITIM/ITAM pair of molecules localized to human chromosome 17. Tissue Antigens. 2000;55:101-109.
3. Clark GJ, Fitzparick S, Kuo CPB, et al. The CMRF-35 family of molecules - A new leucocyte receptor complex on chromosome 17. Res Trends Curr Trends Immunol. 2003;5:55-64.
4. Aguilar H, Alvarez-Errico D, Garcia-Montero AC, et al. Molecular characterization of a novel immune receptor restricted to the monocytic lineage. J Immunol. 2004;173:6703-6711.
5. Clark G, Munster D, Yusuf S, et al. Eighth leucocyte differentiation antigen workshop DC section summary. Cell Immunol. 2005;236:21-28.
6. Figdor CG, de Vries IJ, Lesterhuis WJ, et al. Dendritic cell immunotherapy: mapping the way. Nat Med. 2004;10:475-480.
7. Jeras M, Bergant M, Repnik U. In vitro preparation and functional assessment of human monocyte-derived dendritic cells-potential antigen-specific modulators of in vivo immune responses. Transpl Immunol. 2005;14:231-244.
8. Peng JC, Thomas R, Nielsen LK. Generation and maturation of dendritic cells for clinical application under serum-free conditions. J Immunother. 2005;28:599-609.
9. Elkord E, Williams PE, Kynaston H, et al. Human monocyte isolation methods influence cytokine production from in vitro generated dendritic cells. Immunology. 2005;114:204-212.
10. Scandella E, Men Y, Legler DF, et al. CCL19/CCL21-triggered signal transduction and migration of dendritic cells requires prostaglandin E2. Blood. 2004;103:1595-1601.
11. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 1994;179:1109-1118.
12. Sallusto F, Cella M, Danieli C, et al. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med. 1995;182:389-400.
13. Luft T, Maraskovsky E, Schnurr M, et al. Tuning the volume of the immune response: strength and persistence of stimulation determine migration and cytokine secretion of dendritic cells. Blood. 2004;104:1066-1074.
14. Thurner B, Roder C, Dieckmann D, et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods. 1999;223:1-15.